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Abstract
Background: Artemisinin combination therapies (ACTs) are currently the preferred option for treating uncomplicated
malaria. Dihydroartemisinin-piperaquine (DHA-PQP) is a promising fixed-dose ACT with limited information on its safety and
efficacy in African children.
Methodology/Principal Findings: The non-inferiority of DHA-PQP versus artemether-lumefantrine (AL) in children 6–59
months old with uncomplicated P. falciparum malaria was tested in five African countries (Burkina Faso, Kenya,
Mozambique, Uganda and Zambia). Patients were randomised (2:1) to receive either DHA-PQP or AL. Non-inferiority was
assessed using a margin of 25% for the lower limit of the one-sided 97.5% confidence interval on the treatment difference
(DHA-PQP vs. AL) of the day 28 polymerase chain reaction (PCR) corrected cure rate. Efficacy analysis was performed in
several populations, and two of them are presented here: intention-to-treat (ITT) and enlarged per-protocol (ePP). 1553
children were randomised, 1039 receiving DHA-PQP and 514 AL. The PCR-corrected day 28 cure rate was 90.4% (ITT) and
94.7% (ePP) in the DHA-PQP group, and 90.0% (ITT) and 95.3% (ePP) in the AL group. The lower limits of the one-sided
97.5% CI of the difference between the two treatments were 22.80% and 22.96%, in the ITT and ePP populations,
respectively. In the ITT population, the Kaplan-Meier estimate of the proportion of new infections up to Day 42 was 13.55%
(95% CI: 11.35%–15.76%) for DHA-PQP vs 24.00% (95% CI: 20.11%–27.88%) for AL (p,0.0001).
Conclusions/Significance: DHA-PQP is as efficacious as AL in treating uncomplicated malaria in African children from
different endemicity settings, and shows a comparable safety profile. The occurrence of new infections within the 42-day
follow up was significantly lower in the DHA-PQP group, indicating a longer post-treatment prophylactic effect.
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Introduction
Artemisinin-based combination therapies (ACTs) are highly
efficacious and fast acting antimalarial medicines. The World
Health Organization (WHO) recommends their use for treating
uncomplicated malaria [1]. In Africa, their introduction on a wide
scale began in 2003 and currently most African countries have
adopted or are using ACTs as first or second line treatments,
either artesunate-amodiaquine or artemether-lumefantrine (AL)
[2], available as co-formulations produced under GMP, though
the former is also used as a co-blistered or non-co-formulated
product. The co-formulation of dihydroartemisinin (DHA), the
active metabolite of artemisinin derivatives, with piperaquine
(PQP), a bisquinoline structurally close to chloroquine, seems to be
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a promising combination and a good alternative to AL, whose
optimal use in the public health system is challenged by the twice-
daily dosing scheme and the need for co-administration with fatty
food [3], necessary for improving the absorption of lumefantrine.
DHA-PQP provides a simpler dosage scheme (a single daily dose
over 3 days) than AL and is generally administered without specific
food instructions, though recent data indicate that co-administra-
tion with fat (milk, biscuit, or other food) increases bio-availability
of piperaquine and possibly efficacy [4].
Several trials [5–8] have assessed DHA-PQP safety, efficacy and
effectiveness [9], mostly in Asia, reporting an efficacy of about
90% over 28–63 days [8]. There is little information on the safety
and efficacy of DHA-PQP in African children, as only a few single-
centre trials [10–13] have been done in Africa. DHA-PQP is
registered in several countries in Africa and South-East Asia and
has been widely used in Vietnam or Cambodia, though these
formulations are not manufactured according to internationally
recognised GMP. In 2005, a public-private partnership pro-
gramme funded by the Medicines for Malaria Venture (MMV)
and led by the Italian Company Sigma-Tau I.F.R. SpA (Rome) in
collaboration with the University of Oxford was set up to fill the
gaps needed for the international registration of DHA-PQP. This
included a phase III, randomized multicentre trial to test the non-
inferiority of DHA-PQP compared with AL in treating uncom-
plicated malaria in African children.
Methods
The protocol for this trial and supporting non-inferiority
adapted [14] CONSORT checklist are available and annexed as
supporting information; see Protocol S1 and Checklist S1.
Ethical Considerations and Patient Safety
The study protocol was approved by the Institutional Review
Board of the Institute of Tropical Medicine, Antwerp, the Ethical
Committee of the Antwerp University Hospital, the University of
Heidelberg Ethics Committee and by the National Ethics Review
Committee or Institutional Review Board at each trial site. The
trial was conducted under the provisions of the Declaration of
Helsinki and in accordance with Good Clinical Practices
guidelines set up by the International Conference on Harmoni-
zation. A Study Steering Committee, a Data Monitoring
Committee and a Clinical Development Committee were created
prior to the beginning of the trial, and worked independently to
harmonise and monitor the study. The trial was registered prior to
the enrolment of the first patient in the International Standard
Randomized Controlled Trials Register, number ISRCTN
16263443, at http://www.controlled-trials.com/isrctn.
Study Design, Sites and Concealment of Patient
Allocation
Between August 2005 and July 2006, a randomised, open-label,
multicentre clinical trial was carried out in five African sites (Nanoro,
Burkina Faso; Kilifi, Kenya; Manhic¸a, Mozambique; Mbarara,
Uganda; and Ndola, Zambia). Characteristics of the five sites are
summarized in Table 1. [ONLINE PUBLICATION ONLY]
Children 6–59 months old attending the health facilities with
uncomplicated malaria were included in the study if they fulfilled the
following inclusion criteria: body weight .5 kg; microscopically
confirmed Plasmodium falciparum mono-infection with asexual parasite
densities between 2,000 and 200,000/ml; fever (axillary temperature
$37.5uC) or history of fever in the preceding 24 h. Patients were not
recruited if they met at least one of the following exclusion criteria:
severe malaria [15], or other danger signs; acute malnutrition (weight
for height ,70% of the median National Center for Health
Statistics/WHO reference) or any other concomitant illness or
underlying disease; contra-indication to receive the trial drugs or
ongoing prophylaxis with drugs having antimalarial activity. Patients
satisfying the inclusion/exclusion criteria were enrolled if the parent/
guardian signed a detailed written informed consent.
Table 1. Basic characteristics of the 5 African sites (online publication only).
Nanoro, Centre Muraz
(Burkina Faso)
Kilifi, KEMRI
(Kenya)
CISM, Manhic¸a
(Mozambique)
Epicentre,
Mbarara (Uganda)
TDRC, Ndola
(Zambia)
Characteristics of the area Rural Rural Rural Rural Periurban
Malaria endemicity Mesoendemic Mesoendemic Mesoendemic Mesoendemic Mesoendemic
Seasonality High transmission between
June and December
Perennial, with two
peak seasons:
Jul-Sep; Dec-Jan
Perennial with
marked seasonality
(Oct-April)
Perennial with
two peaks:
April and October
High transmission
between November
and May
Entomological Inoculation rate (EIR) 100 to 160 (2003) 22 to 531 38 (2002)2 Not available Not available
Site area under Demographic
surveillance system (DSS)
No Yes Yes No No
ITNs coverage ,10% Subsidised available ,10% 11,4% Approximately 30%
First line treatment at the time of the study Amodiaquine-artesunate
or AL
SP, and then AL Amodiaquine-SP AL AL
Documented resistance to chloroquine 35% 60% 69%3 81%4 60%
Dates start patients’ recruitment/end follow up 16 Aug 2005/18 Jan 2006 22 Sep 2005/14
July 2006
14 Nov 2005/10
July 2006
17 Oct 2005/11
July 2006
16 Nov 2005/10
July 2006
1Mbogo CM, Mwangangi JM, Nzovu J, Gu W, Yan G, Gunter JT, et al. Spatial and temporal heterogeneity of Anopheles mosquitoes and Plasmodium falciparum
transmission along the Kenyan coast. Am J Trop Med Hyg. 2003 Jun; 68(6):734–42.
2Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Milman J, et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young
African children: randomised controlled trial. Lancet. 2004 Oct 16; 364(9443):1411–20.
3Abacassamo F, Enosse S, Aponte JJ, Gomez-Olive FX, Quinto L, Mabunda S, et al. Efficacy of chloroquine, amodiaquine, sulphadoxine-pyrimethamine and combination
therapy with artesunate in Mozambican children with uncomplicated malaria. Trop Med Int Health. 2004 Feb; 9(2):200–8.
4Legros D, Johnson K, Houpikian P, Makanga M, Kabakyenga JK, Talisuna AO, et al. Clinical efficacy of chloroquine or sulfadoxine-pyrimethamine in children under five
from south-western Uganda with uncomplicated falciparum malaria. Trans R Soc Trop Med Hyg. 2002 Mar-Apr; 96(2):199–201.
doi:10.1371/journal.pone.0007871.t001
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Patients were individually randomised according to a 2:1 (DHA-
PQP:AL) scheme, so as to have more patients in the DHA-PQP
arm to provide better estimates for its cure rates and more cases
for the integrated safety data base. A randomisation list stratified
by country was generated by an independent off site contract
research organisation (CRO), with each treatment allocation
concealed in opaque sealed envelopes that were opened only after
the patient’s recruitment.
Both drugs were administered under direct supervision during 3
consecutive days, according to the patient’s body weight. AL
(CoartemTM, Novartis, Switzerland) was administered twice a day
(at enrolment and at 8, 24, 36, 48 and 60 h) according to the
following dosage: weight 5–14 kg: one tablet per dose; weight 15–
24 kg: two tablets per dose; weight 25–34 kg: three tablets per
dose. DHA-PQP (EurartesimTM, Sigma-Tau, Italy) was given
once daily, at the standard dosage of 2.25 mg/kg and 18 mg/kg
per dose of DHA and PQP, respectively, rounded up to the nearest
half tablet. To facilitate the correct dosing of DHA-PQP, two
formulations were used (DHA 20 mg + PQP 160 mg and DHA
40 mg + PQP 320 mg). In case of vomiting, a full dose was
repeated if this occurred within the first half an hour, or half a dose
if it occurred between 30 minutes and 1 h. AL was administered
concomitantly with milk (as recommended by the manufacturer)
while for DHA-PQP no specific instructions regarding co-
administration with food were given. For infants, drugs were
crushed, mixed with water and administered as slurry.
Both patient allocation to the different analysis populations and
assessment of the primary end-point were made by staff blinded to
the treatment assignment and before availability of the PCR
results.
Treatment Follow-Up, Clinical and Laboratory Procedures
All children were kept at the health facility for the 3-day dosing
period. The mother/guardian was asked to return with the child
for scheduled visits on days 7, 14, 21, 28, 35 and 42 post-
treatment, or if any symptoms occurred. Field workers traced
patients missing any visit. For each visit, a physical examination
was performed by the study clinicians, vital signs were recorded,
and axillary temperature measured with an electronic thermom-
eter. Adverse events and serious adverse events were recorded and
monitored throughout the study. A 12-lead electrocardiogram
(ECG) was performed at enrolment and repeated on days 2 and 7
to assess any QT/QTc interval prolongation. Any ECG
abnormality detected at enrolment requiring urgent management
was considered an exclusion criterion. All ECG records were
transmitted daily online to a central cardiologist (Paris, France)
who interpreted them in a blinded manner, and feedback was sent
to the sites as soon as available. The QTc interval (ms) was
evaluated after correcting for the heart rate with Bazett’s or
Fridericia’s formulae and classified according to the following
categories: Normal ,430 ms; Borderline: 431–450 ms; Prolonged
.450 ms.
The study was supervised by monthly monitoring visits. Rescue
treatment for recurrent parasitaemia was according to local
national guidelines. All participants, with the exception of those in
Kilifi, received a free insecticide-treated bed net at recruitment.
Capillary or venous blood was taken at every visit. Thick and
thin blood films were prepared, dried and Giemsa-stained, and
parasite density estimated by counting the number of asexual
parasites in 200 white blood cells (WBC), assuming a standard
WBC count of 8,000/ml. Quality control was performed in blind
conditions on 20% of all the slides at a central laboratory. Samples
for haematology (full blood count) and biochemistry (liver and
renal function) were taken at enrolment, at days 3, 28 and 42, and
at any other visit if judged necessary by the clinician. For PCR
analysis, three blood spots were collected on filter paper
(Whatmann 3 MM) at enrolment and at any visit after day 7.
Each filter paper was dried and individually stored in a plastic bag
containing silica gel. All filter papers were subsequently transferred
to the Institute of Tropical Medicine (Antwerp, Belgium) where
centralised genotyping was conducted. Purification of DNA was
conducted as previously described [16]. Three polymorphic
genetic markers MSP1, MSP2 and GluRP were used to distinguish
recrudescence from new infections [17,18]. Recrudescence was
defined as at least one identical allele for each of the three markers
in the pre-treatment and post-treatment samples. New infections
were diagnosed when all alleles for at least one of the markers
differed between the two samples. All gels were re-read under
blinded conditions by an independent expert (National Museum of
Natural History, Paris, France). In addition, 20% of the filter
papers were re-analysed and assessed by an independent
laboratory (Shoklo Malaria Research Unit, Mae Sot, Thailand).
Outcome Classification
The primary endpoint was the PCR-corrected adequate clinical
and parasitological response (ACPR) at day 28; secondary efficacy
outcomes included PCR-corrected cure rates at days 14 and 42,
PCR-uncorrected cure rates at days 14, 28 and 42; parasite and
fever clearance times, presence and clearance of gametocytes, and
haemoglobin (Hb) changes from baseline to day 28. All standard
safety outcomes such as incidence of adverse events, changes from
baseline on haematology and clinical chemistry parameters, ECG
findings and vital sign variation during the study were also
evaluated.
Treatment outcome was analysed in two ways. The first, based
on a pre-defined (in the protocol) procedure further developed
with the Data Monitoring and the Clinical Development
Committees, complemented the WHO definitions (see below)
with a set of rules allowing the evaluation of each individually
randomised patient, e.g. patients having taken not-allowed anti-
malarial drugs or with halfway missing data such as blood
parasitaemia (Table 2). Such an approach was defined as primary
because it was deemed in line with the requirements of the most
stringent regulatory authorities. All cases not strictly matching the
WHO definitions and/or the described procedure were reviewed
individually at the data review meetings in blind conditions. The
second approach, based on the standard definitions of early/late
clinical and parasitological failure (World Health Organization)
[19], was used to allow comparison with previously published
results. Accordingly, true treatment failure (TTF) was defined as
the sum of the early and late (either LPF or LCF) treatment
failures occurring until Day 13 (recrudescence by default) and the
late treatment failures from Day 14 onwards classified as
recrudescence by PCR analysis.
Statistical Analysis
Several populations were defined for the analysis and two of
them (intention-to-treat, ITT, and enlarged per-protocol, ePP),
despite not being the primary ones as defined by the protocol, are
presented here on the basis of their comparability with the
populations discussed in previous published studies, their clinical
relevance and the fact that conclusions are similar on all
considered populations. The ITT included all randomised patients
having taken at least one dose of the study treatments. The ePP
population included all randomised patients fulfilling the protocol
eligibility criteria, having taken at least 80% of the study
medication when not previously classified as early treatment
failures, completing the day 28 assessment and having an
Dihydroartemisinin-Piperaquine
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evaluable PCR in case of recurrent parasitaemia. Table 2 provides
details for patient classification in these two populations.
Primary efficacy analysis was based on a 97.5% (one-sided)
confidence interval (CI) computed on the difference between the day
28 PCR-corrected cure rates (defined as in Table 2) of DHA-PQP
and AL. To prove non-inferiority, the lower limit of this CI was to be
within 25%, the pre-established non-inferiority margin. The Wald
method (without continuity correction) was used to compute the CI,
as this method was known to provide control of type I error around
the nominal level for the 2:1 allocation, and also in the context of a
hypothesis test of non-inferiority [20]. PCR-corrected and uncor-
rected cure rates at the other time points were assessed similarly. TTF
was estimated with the Kaplan-Meier method as suggested byWHO,
in the ePP population. Patients withdrawing the study, with a new
infection, or with a non-interpretable or missing PCR were censored
at the withdrawal or PCR sampling time.
Survival analysis was applied also to the new infections. In this
case censoring was applied to recrudescences.
Cure rates were also stratified by country and age (age groups:
#12 months;.12 months), though the study was not powered for
proving efficacy within each country or age group. The Breslow-
Day test, or logistic regression when the former was not applicable,
was used to assess homogeneity across countries and age groups.
For exploratory testing, categorical variables were compared using
x2 or Fisher’s exact test, and continuous variables using the
Student t-test for independent samples.
Rates of person-gametocyte-weeks for measuring gametocyte
carriage and transmission potential were calculated as the number
of weeks in which blood slides were positive for gametocytes
divided by the total number of follow-up weeks and expressed per
1,000 person-weeks.
All safety variables were analysed in the ITT population.
Sample Size Calculation
This study was designed as a non-inferiority trial. Assuming
80% statistical power, a one-sided a level of 2.5%, and adopting
an unequal 2:1 randomisation ratio, 1,500 patients (1000 DHA-
PQP, 500 AL) were needed to show that the difference of the day
28 PCR-corrected cure rates between DHA-PQP and AL was
within 25%, assuming a response rate for AL of at least 92%.
Results
Trial Profile and Baseline Characteristics
Overall, 2,001 patients were screened, and 1,553 recruited and
randomised to receive the study drugs (1,039 DHA-PQP and 514
AL) (Figure 1). Five patients were excluded from all analyses: one
child in each treatment group who did not receive any treatment
and three children in the AL group who were recruited twice (only
data for the first recruitment were retained). A total of 1,548
patients were considered for the ITT population and the safety
analysis, and the ePP population consisted of 1,425 patients. The
attrition rate of the ePP population as compared to the ITT was
approximately 8% and was due to lost-to-follow-up (,2%) or
major protocol violations (,6%). These proportions were equally
distributed between treatments (data not shown).
Randomisation generated comparable groups between coun-
tries and overall (Table 3).
Efficacy Results
DHA-PQP was as efficacious as AL. The day 28 PCR-corrected
cure rate was 90.4% (ITT) and 94.7% (ePP) in the DHA-PQP group,
Table 2. Day 28 and Day 42 uncorrected ACPR (steps 1–11) and PCR-corrected ACPR (steps 1–16) in the different populations of
analysis.
Step Event to be assessed ePP ITT
1 Withdrawal BEFORE OR AT D28: any reason except lost to follow-up (LFU) Depending on reason, a
patient can be: Excluded or Failure
Failure
2 Withdrawal BEFORE OR AT D28: LFU Excluded Failure
3* Withdrawal AFTER D28: any reason except LFU Failure Failure
4* Withdrawal AFTER D28: LFU Failure Failure
5 ETF, LCF, and LPF in accordance with the WHO criteria Failure Failure
6** Presence of major protocol violations Excluded No effect
7** Occurrence of adverse events highlighting recurrence of malaria Failure Failure
8** Presence of missing parasitaemia at two or more consecutive scheduled visits or presence
of an isolated missing parasitaemia not preceded and followed by a negative parasitaemia
Failure Failure
9** Administration of drugs with a known or suspected anti-malaria action as rescue treatment Failure Failure
10** Administration of drugs with a known or suspected anti-malaria action as non rescue treatment Excluded Failure
11** Administration of anti-malarial drugs for P. vivax, P. malariae, or P. ovale
during the course of the study in patients not classified as ETF/LTF
Failure with new infection Failure with new infection
12 PCR not done IN (DAY 4–DAY 13) Recrudescence Recrudescence
13 PCR: non interpretable or missing or not done IN (DAY 14–D28) Excluded Recrudescence
14** PCR: non interpretable or missing or not done AFTER D28 Rule*** Recrudescence
15 PCR =new infection or uncorrected ACPR= Failure with new infection Success Success
16 PCR = recrudescence Recrudescence Recrudescence
*For the Day 42 endpoint.
**All such cases were individually revised at the Blind Data Review meeting. Protocol violations were pre-defined.
***Result ‘‘recrudescence’’ or ‘‘new infection’’ was assigned according to the ratio between these outcomes in the patients with a valid PCR result at the corresponding time
point and within each treatment group, separately considered.
doi:10.1371/journal.pone.0007871.t002
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and 90.0% (ITT) and 95.3% (ePP) in the AL group (ITT: p=0.820;
ePP: p=0.650). The lower limits of the one-sided 97.5% CIs on the
differences between the two treatments were 22.80% and 22.96%,
in the ITT and ePP populations, respectively (Table 4 and Figure 2).
The analyses in the other populations and all sensitivity analyses
confirmed the robustness of these results. The day 42 PCR-corrected
cure rates were lower than those at day 28 but similar for the two
treatments for the ITT population (Table 4). However, the lower
limit of the one-sided 97.5%CI on the cure rate difference for the ePP
population was 25.29%, a value slightly below the pre-established
non-inferiority margin (Table 4 and Figure 2). The details of the
classification of patients for the PCR-corrected response both in the
ITT and ePP populations are presented in Table 4 for both the
analyses at day 28 and day 42. The percentage of recrudescent
infections and new infections, as detected by PCR at or before day 28,
was lower in the DHA-PQP group with respect to the AL group,
while there were more withdrawals and/or treatment failures at or
before day 14 in the DHA-PQP group compared with the AL group
(Table 4). At day 42, the findings were similar with slightly more
recrudescent infections in the DHA-PQP group.
The day 28 PCR-corrected cure rates in infants (6–11 months-
old) were similar to those in older children and above 90% in both
treatment groups (ITT: DHA-PQP 90.70%, AL 92.65%,
p= 0.643, 97.5% CI.29.92%).
The uncorrected cure rates were significantly higher in the
DHA-PQP group, both at day 28 (ITT: DHA-PQP 87.7% vs. AL
76.7%, p,0.001, 97.5% CI.6.82%; ePP: DHA-PQP 91.99% vs.
AL 81.03%, p,0.001, 97.5% CI.6.99%) and at day 42 (ITT:
DHA-PQP 74.08% vs. AL 64.71%, p,0.001, 97.5% CI.4.45%;
ePP: DHA-PQP 77.63% vs. AL 68.75%, p,0.001, 97.5%
CI.3.90%). This was mainly due to fewer late failures later
classified as new infections in the DHA-PQP as compared to the
AL arm. In the ITT population, new infections until day 42
occurred significantly less in the DHA-PQP group (Kaplan-Meier
estimate: 13.55%; 95% CI: 11.35%–15.76%) than in the AL
group (Kaplan-Meier estimate: 24.00%; 95% CI: 20.11%–
27.88%) (Figure 3). Similar results were obtained in the ePP
population (data not shown).
When the day 28 PCR-corrected cure rates were analysed by
country, the heterogeneity test was borderline significant at the
Figure 1. Trial profile.
doi:10.1371/journal.pone.0007871.g001
Dihydroartemisinin-Piperaquine
PLoS ONE | www.plosone.org 5 November 2009 | Volume 4 | Issue 11 | e7871
10% level only in the ePP population (ITT: p= 0.324; ePP:
p = 0.082), suggesting some minor differences among sites
(Figure 2). However, the CIs adjusted by country were almost
identical to the unadjusted ones (data not shown). At day 42, the
heterogeneity test was not statistically significant in either the ITT
or the ePP populations (ITT: p= 0.582; ePP: p = 0.703).
Heterogeneity across countries was more marked for the
uncorrected cure rates at day 28 (ITT and ePP: p,0.001), while
at day 42 the heterogeneity test was borderline significant only in
the ePP population (ITT: p= 0.186; ePP: p= 0.051). However,
with the exception of Kenya, such differences on the uncorrected
cure rates were of a quantitative type, i.e. rather in the size of the
treatment effect across countries, not in its direction, always
favouring DHA-PQP.
When considering the WHO standard definition of TTF, the
two treatment groups were similar at day 28 (Kaplan-Meier
estimate in ePP: DHA-PQP 3.78% [95%CI: 2.57%–5.00%] vs AL
3.19% [95%CI: 1.54%–4.84%], p = 0.528), while at day 42 TTF
tended to be lower in the AL group (Kaplan-Meier estimate in
ePP: DHA-PQP 6.86% [95%CI: 5.22%–8.50%] vs AL 4.52%,
[95%CI: 2.52%–6.51%], p= 0.119).
Parasite clearance was rapid in both treatment groups (Kaplan-
Meier estimate of median time was 2 days in each group, in both
populations). About 60% of patients had fever at baseline while at
day 2 more than 97% of patients were afebrile in both treatment
groups. Gametocyte prevalence at recruitment was similar in both
study arms (ITT: DHA-PQP 11.75%; AL 12.94%, p= 0.501; ePP:
DHA-PQP 11.55%; AL 13.36%, p= 0.326). However, gameto-
cyte carriage measured as rate of person-gametocyte-weeks was
significantly higher in the DHA-PQP group than in the AL group,
both for the ITT (DHA-PQP: 43.97/1,000; AL: 21.43/1,000;
p = 0.005) and the ePP (DHA-PQP: 42.65/1,000; AL: 21.23/
1,000; p = 0.006) populations.
Table 3. Baseline characteristics (ITT population).
Variable
DHA-PQP
(N=1038) AL (N=510)
Gender M/F (%M/%F) 525/513 (50.1/49.4) 281/229 (55.1/44.9)
Age in years (mean6SD) 2.4261.14 2.4361.16
Weight in kg (mean6SD) 11.1962.55 11.2862.67
Fever (n (%)) 624 (60.12) 307 (60.20)
Temperature in uC (mean6SD) 37.8861.22 37.8661.18
Parasite density (geometric mean) 24557 25884
Presence of Gametocytes (n (%)) 122 (11.75) 66 (12.94)
Hb in g/L (mean6SD) 89.23618.15 90.59618.20
Anaemia ( = Hb,7 g/dL) (n (%)) 141 (13.58) 63 (12.35)
Leucocytes in 10ˆ9/L (mean6SD) 9.6264.15 9.5963.94
Platelets in 10ˆ9/L (mean6SD) 182.846108.70 181.596106.74
Splenomegaly (n (%)) 41 (3.95) 19 (3.73)
Hepatomegaly (n (%)) 6 (0.58) 3 (0.59)
ALAT in IU/L (mean6SD) 34.08661.34 31.08636.23
Bilirubin in mg/dl (mean6SD) 0.9761.04 0.9460.81
Creatinine in U/L (mean6SD) 40.96617.91 41.16619.17
doi:10.1371/journal.pone.0007871.t003
Table 4. PCR-Corrected and Uncorrected Adequate Clinical and Parasitological Response (ACPR) by time point in ITT and ePP Population.
Day 28 Day 42
DHA-PQP AL
Lower Limit of
one-sided 97.5% CI
on difference DHA-PQP AL
Lower Limit of
one-sided 97.5%
CI on difference
PCR-Corrected Cure Rate (n (%)) in ITT 938 (90.37) 459 (90.00) 22.80 895 (86.22) 442 (86.67) 24.06
Uncorrected Cure Rate (n (%)) in ITT 910 (87.67) 391 (76.67) 6.82 769 (74.08) 330 (64.71) 4.45
Total number of failures in ITT (PCR-uncorrected) 128 (12.33) 119 (23.33) 269 (25.92) 180 (35.29)
Recrudescences by PCR 14 (1.35) 11 (2.16) 41 (3.95) 17 (3.33)
Recrudescences due to informative withdrawals
(including LFU) or failure before D14 (PCR not needed)
65 (6.26) 26 (5.10) 65 (6.26) 26 (5.10)
Recrudescences imputed (PCR missing, indet., not done) 21 (2.02) 14 (2.75) 37 (3.56) 25 (4.90)
New Infection by PCR 27 (2.60) 64 (12.55) 122 (11.75) 105 (20.59)
New Infection ? from Plasmodium Falciparum 1 (0.10) 4 (0.78) 4 (0.39) 7 (1.37)
PCR-Corrected Cure Rate (n (%)) in ePP 910 (94.69) 442 (95.26) 22.96 879 (91.47) 436 (93.97) 25.29
Uncorrected Cure Rate (n (%)) in ePP 884 (91.99) 376 (81.03) 6.99 746 (77.63) 319 (68.75) 3.90
Total number of failures in ePP (PCR-uncorrected) 77 (8.01) 88 (18.97) 215 (22.37) 145 (31.25)
Recrudescences by PCR 14 (1.46) 11 (2.37) 41 (4.27) 16 (3.45)
Recrudescences due to informative withdrawals
or failure before D14 (PCR not needed)
37 (3.85) 11 (2.37) 37 (3.85) 11 (2.37)
Recrudescences imputed (rule for missing PCR) 0 0 4 (0.42) 1 (0.22)
New Infections imputed (rule for missing PCR) 0 0 11 (1.14) 8 (1.72)
New Infection by PCR 25 (2.60) 62 (13.36) 118 (12.28) 102 (21.98)
New Infection ? from Plasmodium Falciparum 1 (0.10) 4 (0.86) 4 (0.42) 7 (1.51)
Note: In ITT, percentages are based on N= 1038 (DHA-PQP) and N= 510 (AL); in ePP, percentages are based on N= 961 (DHA-PQP) and N= 464 (AL).
doi:10.1371/journal.pone.0007871.t004
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Haemoglobin changes from baseline to day 28 were comparable
between treatment groups (data not shown) while the change from
baseline to the last available data was significantly higher in the
DHA-PQP group than in the AL group (ITT: 17.0618.18 g/L vs
14.27618.54 g/L, p = 0.007; ePP: 17.19617.96 g/L vs
15.07618.56 g/L, p= 0.044).
Safety Results
Both DHA-PQP and AL were well tolerated with the majority
of adverse events of mild or moderate severity, and consistent with
symptoms attributable to malaria (Table 5). There were no
significant differences in the occurrence of events, including
serious adverse events. Gastrointestinal tolerability of both drugs
was similar (DHA-PQP: 207/1038, 19.9%; AL: 92/510, 18.0%),
with the majority of events being mild. Cutaneous adverse events
were infrequent, and mainly involved minor dermatitis or rash
(DHA-PQP: 70/1038, 6.7%; AL: 29/510, 5.7%). Three patients
developed urticaria (one (0.1%) in the DHA-PQP group and two
(0.4%) in the AL group) and three more developed mild
hypersensitivity (two (0.2%) in the DHA-PQP group and one
(0.2%) in the AL group). None of them required hospitalization.
Occurrence of laboratory AEs, e.g. neutropenia (DHA-PQP: 18/
1038, 1.7%; AL: 12/510, 2.4%) and altered liver enzymes (ALT)
(DHA-PQP: 20/1038, 1.9%; AL: 19/510, 3.7%), was similar
between the two treatment groups.
ECG was performed in more than 98% of patients at day 0 and
day 2, always before the administration of the treatment (96% of
patients had ECG also at day 7). In the DHA-PQP group, the
proportion of patients with borderline (29.1%) and prolonged
(9.1%) QTc interval at day 2 corrected by the Bazett’s method was
higher than in the AL group (19.8% and 6.9%) (p,0.001).
However, this was not confirmed when applying the Fridericia’s
Figure 3. Kaplan Meier curve showing the cumulative proportion until day 42 of children with new infections (ITT population).
doi:10.1371/journal.pone.0007871.g003
Figure 2. PCR-corrected Adequate Clinical and Parasitological Response (ACPR) (ePP population) by country and by time point.
doi:10.1371/journal.pone.0007871.g002
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correction as the corresponding proportions were 1.0% and 0.2%
in the DHA-PQP group and 1.2% and 0.2% in the AL group
(p = 0.76). In addition, a $60 ms increase of the QTc interval
between day 0 and day 2 (Bazett’s correction) was observed in just
2.7% (DHA-PQP) and 2.0% (AL) patients; only two patients per
group showed a QTc at day 2 higher than 500 ms. When
considering the occurrence of the AE ‘‘Electrocardiogram QT
prolonged’’, similar percentages (DHA-PQP: 26/1038, 2.5%; AL:
13/510, 2.6%) were observed in the two treatment groups
(Table 5).
No other difference between groups was observed during the
follow up (data not shown).
Two deaths (one per group) occurred during the study. In
Uganda, a 3 year-old girl died 24 h after commencing treatment
with DHA-PQP. Sepsis or severe malaria was considered by the
investigating clinician as the most likely cause. In Mozambique, an
18 month-old girl died 7 h after the first dose of AL. Severe
malaria was considered the most likely cause of death, although
other aetiologies such as sepsis, hypoglycaemia, heart conditions or
bronco-aspiration could not be excluded. No autopsy could be
performed in these two children and a causal relationship with the
treatment could not be ruled out.
Discussion
The fulfilment of the non-inferiority criterion on all analysis
populations and the confirmation that in this study the comparator
treatment had the expected efficacy [12,21] proved that DHA-PQP
is non inferior to AL in treating African children aged 6–59 months
with uncomplicated malaria. The two treatments had similar safety
profiles. Our study confirms the results of previous trials in Asia [8]
and Africa [10–13] that found DHA-PQP to be as effective as other
ACTs, including AL. A recent study in Papua New Guinea (PNG)
reported a significantly higher cure rate (adequate clinical and
parasitological response) in children treated with AL as compared to
DHA-PQP [7]. The reasons for such discordant results are unclear
though the authors mention the cross-resistance between chloro-
quine and PQP. However, PQP, though structurally related to
chloroquine, has been shown to be effective in vitro against
chloroquine-resistant strains [8,22]. In addition, it has been
suggested that the lower-than-expected DHA-PQP efficacy reported
in PNG may be due to administration of the treatment without any
food [4]. Indeed, PQP is highly lipid-soluble and its oral
bioavailability is enhanced when given with food [23,24], though
an additional study in Vietnamese healthy volunteers reports no
influence of food intake (standardised Vietnamese meal) on PQP
pharmacokinetics [25]. The issue on whether to recommend the
administration of DHA-PQP with a biscuit or a glass of milk remains
unanswered. Though co-administration with food may improve the
drug’s bioavailability, it is unclear whether this will translate in a
higher efficacy. In our study, DHA-PQP was given without specific
instructions regarding co-administration with food but its efficacy at
day 42 was over 90%, similar to that reported in a study carried out
in Uganda [10] but lower than in two other African studies [12,13].
Moreover, no clinically relevant heterogeneity was shown across the
five African countries despite the high chloroquine resistance
previously reported from most study sites [26]. When taking into
account all recurrent infections observed during the follow up
period, i.e., without the PCR correction, the cure rates for DHA-
PQP were significantly better than AL, indicating a better post-
treatment prophylaxis (PTP) than AL [27] and confirming that
chloroquine resistance did not interfere with DHA-PQP efficacy.
The significantly higher Hb change from baseline to the last
available data in the DHA-PQP group is in line with this
observation. Therefore, the longer PQP’s elimination half-life (about
20 days) as compared to lumefantrine (4–10 days), provides a longer
PTP, prevents the emergence of new infections and improves the
patient’s haematological recovery, despite a significant chloroquine
resistance background. While this is clearly an advantage for the
individual, at the population level, it may increase the risk of selecting
resistant parasites among the new infection [28] and stress the need
of matching the large scale deployment of DHA-PQP with the
careful monitoring of resistance [29].
One hundred twenty nine infants aged 6–11 months treated
with DHA-PQP responded as well to treatment as older children,
though the study was not powered to confirm non-inferiority
between the two treatment groups. Infants represent a special
group as they are more at risk of malaria and of receiving
inadequate doses of antimalarial treatments. In Papua, Indonesia,
the PQP plasma concentration at day 7 was the major
determinant of the therapeutic response to DHA-PQP [30]. The
best cut-off for the day 7 PQP concentration predicting any
Table 5. Summary of adverse events (ITT population).
Safety/ITT Population DHA-PQP (N=1038) AL (N=510) p-value
At least one AE (n,%) 823 (79.29%) 411 (80.59%) 0.550
Neutropenia 18 (1.73%) 12 (2.35%)
Vomiting 71 (6.84%) 35 (6.86%)
Gastrointestinal disorders (including vomiting) 207 (19.94%) 92 (18.04%)
Skin and subcutaneous tissue disorders 70 (6.74) 29 (5.69%)
Alanine aminotransferase increased 20 (1.93%) 19 (3.73%)
Electrocardiogram QT prolonged 26 (2.50%) 13 (2.55%)
At least one related AE (n,%) 737 (71.00%) 368 (72.16%) 0.637
At least one SAE (n,%) 18 (1.73%) 5 (0.98%) 0.249
At least one related SAE (n,%) 15 (1.45%) 4 (0.78%) 0.332
At least one AE which caused discontinuation (n,%) 5 (0.48%) 0 0.178
At Least one SAE which caused death (n,%) 1 (0.10%) 1 (0.20%) 0.551
AE=Adverse event; SAE = Serious adverse event; Related SAE= Serious adverse event for which the investigator classifies the relationship to the study drug as unlikely,
possible, probable, definitely related or whose classification is missing.
doi:10.1371/journal.pone.0007871.t005
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treatment failure was 30 ng/ml and children had a higher risk of
having lower levels [31]. Similarly, in PNG, a trend toward a
lower risk of treatment failure (PCR uncorrected) and plasma PQP
levels at day 7 has been reported [7], suggesting that an increase of
the weight-adjusted dosage in children may be required. In our
study, preliminary results on predictors of treatment failure seem
to confirm the need of reviewing and possibly increasing the
weight-adjusted dosage for children.
Patients treated with DHA-PQP had a significantly higher rate
of person-gametocyte-weeks compared with those having re-
ceived AL. This contrasts with a previous study in Papua,
Indonesia, which showed no difference in gametocyte carriage
between DHA-PQP and AL [30], but is in line with comparisons
between DHA-PQP and mefloquine-artesunate, where a higher
production of gametocytes in patients treated with DHA-PQP
was observed [5,9]. Such an effect has been attributed to the lower
dose of artemisinin derivative used in the DHA-PQP. Gameto-
cytaemia is a proxy measure of transmission potential and the
increased gametocyte production related to DHA-PQP use may
be a public health disadvantage that should be nevertheless
balanced against a better PTP, particularly useful in areas of
intense transmission.
Dihydroartemisinin-piperaquine was well tolerated, with few
adverse events of clinical relevance. A higher frequency of
abdominal pain and diarrhoea has previously been reported for
DHA-PQP compared with mefloquine-artesunate [8] but this
disadvantage of DHA-PQP was not observed in this trial where
the comparator treatment was AL. The statistical significant
difference in the QTc interval at day 2 was observed only when
applying Bazett’s but not Fridericia’s correction. This was not
considered as clinical relevant because of the discrepant results
obtained with the 2 methods and because both the proportions of
patients with a QTc prolongation between day 0 and 2 higher
than 60 ms or with an absolute QTc value greater than 500 ms
were extremely low and balanced between groups. Therefore,
considering that no cardiovascular AEs were reported, this study
adds to the evidence [8] that, at therapeutic doses, DHA-PQP and
AL do not have any clinically significant cardiotoxicity.
It has also been previously reported that the only potentially
serious adverse effects of artemisinin derivatives are rare type 1
hypersensitivity reactions [8,32]. However, no evidence of
moderate or severe adverse reactions of this kind was observed
in the current study and this was despite the larger sample size
compared with other published studies in which the number of
patients recruited for each arm did not exceed a few hundred.
Indeed, it is reassuring that no major safety problem has been
observed in more than 1,000 children treated with DHA-PQP.
Nevertheless, such a sample size is unable to detect rare and
unexpected serious adverse events and the development of a
pharmacovigilance system should be a priority, not only for DHA-
PQP but also for all other ACTs. African countries should be
encouraged, as the use of ACTs increases, to establish pharma-
covigilance systems [29] and drug developers and funding agencies
should contribute to their development.
In conclusion, DHA-PQP is a safe, efficacious, tolerable and
affordable new antimalarial treatment option in Africa. Its longer
PTP period may be particularly useful in areas where transmission
is intense, though it may exert an important drug pressure on the
parasite populations, possibly selecting resistant strains. The
deployment of several ACTs as multiple first line treatments
may overcome this problem. Indeed, assuming that different
treatments are used in equal amounts in the host population, the
use of multiple first line therapies would have two main benefits,
i.e. the inability of the parasite to adapt to a variable environment
and the reduced drug pressure as the rate at which a given
treatment is used would be lower than if it was the only one
available [33]. DHA-PQP can definitely play an essential role in
our effort to reduce the currently high malaria burden.
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